Knuff & Co LLC Sells 3,559 Shares of Thermo Fisher Scientific Inc. $TMO

Knuff & Co LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 34.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,669 shares of the medical research company's stock after selling 3,559 shares during the quarter. Thermo Fisher Scientific accounts for 0.9% of Knuff & Co LLC's holdings, making the stock its 27th biggest position. Knuff & Co LLC's holdings in Thermo Fisher Scientific were worth $2,704,000 as of its most recent SEC filing.

• Institutions Love These 3 Companies, Should You As Well?

A number of other institutional investors have also recently bought and sold shares of the stock. CBIZ Investment Advisory Services LLC lifted its position in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $31,000. DiNuzzo Private Wealth Inc. boosted its position in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after buying an additional 61 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd raised its position in Thermo Fisher Scientific by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 77 shares of the medical research company's stock valued at $38,000 after buying an additional 63 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $580.61 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock's 50 day moving average price is $555.23 and its two-hundred day moving average price is $483.27. The firm has a market capitalization of $218.14 billion, a price-to-earnings ratio of 33.54, a P/E/G ratio of 4.28 and a beta of 0.90.

• These 3 Stocks Are Using Buybacks to Signal Market Confidence

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts' consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the previous year, the firm earned $5.28 EPS. The firm's revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

• Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 9.94%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $65,247,057.48. This represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michel Lagarde sold 4,638 shares of the business's stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total value of $2,756,919.96. Following the sale, the chief operating officer owned 23,480 shares of the company's stock, valued at approximately $13,956,981.60. This represents a 16.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,625 shares of company stock worth $38,157,158 in the last 90 days. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. TD Cowen upped their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a "buy" rating in a research report on Thursday, October 23rd. Leerink Partners raised their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an "outperform" rating in a research report on Wednesday, October 22nd. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. Argus raised their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a "buy" rating in a report on Wednesday, October 29th. Finally, UBS Group upped their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a "neutral" rating in a report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $602.35.

Read Our Latest Report on Thermo Fisher Scientific

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

• Five stocks we like better than Thermo Fisher Scientific
• 3 Home Improvement Stocks that Can Upgrade Your Portfolio
• MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?
• Value Investing: Is it a Good Strategy in 2022? Hint: Always
• 3 Stocks Poised to Benefit From Google’s AI Breakthough
• 3 Warren Buffett Stocks to Buy Now
• Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Thermo Fisher Scientific Right Now?

Before you consider Thermo Fisher Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.

While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here